3 not yet recruiting, 3 recruiting, 1 completed. 1 Not applicable, 1 Phase 1, 1 Phase 2, 1 Phase 3, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 1 | Not yet recruiting 1 |
| Phase 1 | 1 | Recruiting 1 |
| Phase 2 | 1 | Completed 1 |
| Phase 3 | 1 | Not yet recruiting 1 |
| Phase 4 | 1 | Not yet recruiting 1 |
Follow Waldenstrom Macroglobulinaemia: new trials by email Literature Review of Waldenstrom Macroglobulinaemia trials Research Report on Waldenstrom Macroglobulinaemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| BLOOD-dose: A Platform Trial Evaluating Dose Optimization in Hematological Diseases. teclistamab OR talquetamab OR elranatamab OR linvoseltamab, BTK inhibitors (ibrutinib and zanubrutinib) - Waldenstrom Macroglobulinaemia, Multiple Myeloma | Phase 4 | Not yet recruiting | Anne Louise Tølbøll Sørensen | 400 | 2027-03-01 | 2026-03-16 |
| Evaluation of Iopofosine I 131 vs. R-CD in WM Patients Iopofosine I 131, Rituximab (active comparator), Cyclophosphamate - Waldenstrom Macroglobulinaemia, Waldenstrom Macroglobulinemia | Phase 3 | Not yet recruiting | Cellectar Biosciences, Inc. | 219 | 2026-12-01 | 2026-08-14 |
| Connected Blood Pressure Monitoring in Patients With Hematologic Malignancies Initiating Covalent BTK Inhibitors Connected home blood pressure monitoring with daily IPA supervision. - Chronic Lymphocytic Leukemia (CLL), Follicular Lymphoma ( FL) | Not applicable | Not yet recruiting | Centre Hospitalier de la côte Basque | 40 | 2026-07-01 | 2026-06-22 |
| This Study Aims to Clarify the Prevalence and Characteristics of Neuropathy, Along With Associated Paraclinical Findings in Patients With Waldenström's Macroglobulinemia (WM) in a Cohort of WM Patients to Optimize the Diagnostic Process Waldenstrom Macroglobulinaemia, Peripheral Neuropathies | Recruiting | Copenhagen University Hospital, Rigshospitalet | 90 | 2025-05-14 | 2025-09-08 | |
| SynKIR-310 for Relapsed/Refractory B-NHL SynKIR-310 - B Cell Lymphoma, NHL, Adult | Phase 1 | Recruiting | Verismo Therapeutics | 36 | 2024-11-01 | 2026-04-14 |
| Early Assessment of Lymphoma Treatment Response Using Phased Variant Analysis With Next-Generation Sequencing ctDNA analyzed by phased variant - Lymphoma, Hodgkin Lymphoma | Recruiting | National Taiwan University Hospital | 200 | 2024-08-09 | 2025-06-17 | |
| A Phase II Trial of Ofatumumab in Subjects With Waldenstrom's Macroglobulinemia Ofatumumab - Waldenstrom Macroglobulinaemia | Phase 2 | Completed | GlaxoSmithKline | 37 | 2009-03-01 | 2017-05-30 |
Waldenstrom Macroglobulinemia (7) · Lymphoma, B-Cell, Marginal Zone (2) · Lymphoma, Follicular (2) · Lymphoma, Mantle-Cell (2) · Dendritic Cell Sarcoma, Interdigitating (1) · Hodgkin Disease (1) · Hypertension (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Lymphoma (1) · Lymphoma, B-Cell (1) · Lymphoma, Large B-Cell, Diffuse (1) · Lymphoma, Non-Hodgkin (1) · Lymphoma, T-Cell (1) · Multiple Myeloma (1) · Peripheral Nervous System Diseases (1)
Blood Protein Disorders (7) · Cardiovascular Diseases (7) · Hematologic Diseases (7) · Hemic and Lymphatic Diseases (7) · Hemorrhagic Disorders (7) · Hemostatic Disorders (7) · Immune System Diseases (7) · Immunoproliferative Disorders (7) · Lymphatic Diseases (7) · Lymphoproliferative Disorders (7) · Neoplasms (7) · Neoplasms by Histologic Type (7) · Neoplasms, Plasma Cell (7) · Paraproteinemias (7) · Vascular Diseases (7)
CLR1404 (1) · Dexamethasone (1) · Rituximab (1) · ibrutinib (1) · ofatumumab (1) · talquetamab (1) · zanubrutinib (1)
Anne Louise Tølbøll Sørensen (1) · Cellectar Biosciences, Inc. (1) · Centre Hospitalier de la côte Basque (1) · Copenhagen University Hospital, Rigshospitalet (1) · GlaxoSmithKline (1) · National Taiwan University Hospital (1) · Verismo Therapeutics (1)
Denmark (2) · United States (2) · Taiwan (1)
Laura A Johnson, PhD (1) · Tai-Chung Huang, Ph.D (1)